LASE Registers 3.87M Shares for Resale, Eyes Pharma Expansion

TL;DR

**LASE's massive share registration by insiders signals potential dilution and a lack of direct capital infusion, making it a risky bet despite new market ventures.**

AI Summary

Laser Photonics Corp (LASE) filed an S-1/A on December 29, 2025, to register the resale of up to 3,871,964 shares of common stock by selling stockholders. These shares include 1,098,902 unregistered shares from a September 2025 Securities Purchase Agreement, 2,197,804 shares issuable upon exercise of Series A and Series B warrants from the same agreement, 76,923 shares from Placement Agent Warrants, 418,000 shares issued to Hudson Global Ventures, LLC from an August 2025 SPA, and 157,258 shares issuable from the Hudson Warrant. The company will not receive proceeds from the resale of shares by selling stockholders, but may receive cash from warrant exercises, though this is uncertain. LASE reported net revenues of $3.4 million by December 31, 2024, and is expanding into the pharmaceutical manufacturing vertical through the acquisition of Control Micro Systems, Inc. (CMS) assets. The company is also developing a Laser Shield Anti-Drone System (LSAD) with affiliate Fonon Technologies and has entered into several licensing agreements with affiliates, including a $350,000 cash payment and 1,000,000 restricted shares for Cold Cutting technology and 3,000,000 restricted shares for laser material processing equipment. Dmitriy Nikitin, through ICT Investments, maintains voting control, with affiliates collectively owning approximately 28% of outstanding common stock prior to this offering.

Why It Matters

This S-1/A filing signals a significant potential increase in LASE's public float, which could exert downward pressure on the stock price, currently at $2.57 per share as of December 19, 2025. Investors should be aware that the company will not directly benefit from the sale of these 3,871,964 shares, only potentially from warrant exercises. The strategic expansion into the pharmaceutical manufacturing vertical via CMS acquisition and the development of the LSAD system could open new revenue streams, but the heavy reliance on related-party licensing agreements with ICT Investments and its affiliates, which collectively own a substantial portion of LASE, raises questions about corporate governance and potential conflicts of interest. Competitors in the laser technology market will be watching LASE's ability to monetize these new ventures and integrate its vertically integrated model effectively.

Risk Assessment

Risk Level: high — The filing explicitly states, "Investing in our securities involves a high degree of risk." This is evidenced by the registration of up to 3,871,964 shares for resale by selling stockholders, which could significantly dilute existing shareholders. Furthermore, the company will not receive any proceeds from these sales, and cash proceeds from warrant exercises are uncertain, as warrants may expire or be exercised on a cashless basis, indicating a lack of immediate capital injection from this offering.

Analyst Insight

Investors should exercise extreme caution and thoroughly evaluate the potential for dilution given the 3,871,964 shares registered for resale. Consider waiting for clearer signs of revenue growth from the new pharmaceutical vertical or the LSAD system, and monitor the impact of the selling stockholders' sales on the stock price before making an investment decision.

Financial Highlights

debt To Equity

N/A

revenue

$3.4 million

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• 3,871,964 — Shares of Common Stock (Maximum shares registered for resale by selling stockholders)
• $3.4 million — Net Revenues (Reported by December 31, 2024)
• $2.57 — Common Stock Price (Last reported sales price on Nasdaq as of December 19, 2025)
• $3.40 — Common Warrants Exercise Price (Exercise price per share for Common Warrants)
• 1,098,902 — Unregistered Shares (Issued under September 2025 Securities Purchase Agreement)
• 1,098,902 — Series A Warrant Shares (Issuable upon exercise of Series A Warrant)
• 1,098,902 — Series B Warrant Shares (Issuable upon exercise of Series B Warrant)
• 418,000 — Hudson Global Shares (Issued to Hudson Global Ventures, LLC)
• 1,000,000 — Restricted Shares (Granted to ICT Investments for Cold Cutting technology license)
• 3,000,000 — Restricted Shares (Granted to Fonon Corporation for laser material processing equipment license)

Key Players & Entities

• Laser Photonics Corp (company) — Registrant
• Wayne Tupuola (person) — CEO of Laser Photonics Corp
• H.C. Wainwright & Co., LLC (company) — Placement Agent for September 2025 Purchase Agreement
• Hudson Global Ventures, LLC (company) — Recipient of 418,000 shares and Hudson Warrant
• ICT Investments, LLC (company) — Affiliate and majority stockholder, holding ~20% of common stock
• Fonon Technologies, Inc. (company) — Affiliate, co-developing LSAD and licensing Cold Cutting technology
• Dmitriy Nikitin (person) — Has voting control of Laser Photonics Corp through ICT Investments
• Control Micro Systems, Inc. (company) — Acquired assets, expanding LASE into pharmaceutical manufacturing
• Nasdaq Capital Market (regulator) — Exchange where LASE common stock trades
• Securities and Exchange Commission (regulator) — Regulatory body for S-1/A filing

FAQ

Risk Factors

• Dependence on Affiliate Transactions [medium — financial]: The company relies on licensing agreements and potential acquisitions with affiliates, such as Fonon Technologies and ICT Investments. These related-party transactions, including a $350,000 cash payment and 1,000,000 restricted shares for Cold Cutting technology, introduce risks related to pricing, terms, and potential conflicts of interest.
• New Market Entry and Integration Risks [medium — operational]: Expansion into the pharmaceutical manufacturing vertical through the acquisition of Control Micro Systems, Inc. (CMS) assets presents integration challenges and operational risks. The success of this diversification strategy is not guaranteed and could strain resources.
• Uncertainty of Warrant Exercise Proceeds [low — financial]: While the S-1/A registers shares issuable upon exercise of Series A and Series B warrants, the company will not receive proceeds from the resale of shares by selling stockholders. Cash proceeds from warrant exercises are uncertain and depend on market conditions and the decision of warrant holders to exercise.
• Compliance with Securities Laws [medium — regulatory]: The registration of resale of a significant number of shares (3,871,964) by selling stockholders requires adherence to SEC regulations. Any misstatements or omissions in the S-1/A filing could lead to regulatory scrutiny and legal liabilities.
• Competition in Laser Technology [medium — market]: The laser technology market is competitive. The company's success in developing and commercializing products like the Laser Shield Anti-Drone System (LSAD) depends on its ability to innovate and compete effectively against established players.
• Concentration of Voting Control [low — financial]: Dmitriy Nikitin, through ICT Investments, maintains voting control, with affiliates collectively owning approximately 28% of outstanding common stock. This concentration of control could limit the influence of other shareholders on corporate decisions.

Industry Context

Laser Photonics Corp operates in the laser technology sector, which is characterized by rapid innovation and diverse applications ranging from industrial manufacturing to defense. The company is attempting to diversify into pharmaceutical manufacturing and defense with its anti-drone system. The competitive landscape includes established players and emerging technology firms, requiring continuous R&D investment and strategic partnerships.

Regulatory Implications

The S-1/A filing subjects Laser Photonics Corp to SEC regulations regarding the resale of securities. Any inaccuracies or omissions could lead to enforcement actions. Furthermore, the company's expansion into defense (anti-drone system) and pharmaceutical manufacturing may attract scrutiny from relevant regulatory bodies in those sectors.

What Investors Should Do

1. Monitor Affiliate Transactions
2. Evaluate Diversification Strategy
3. Assess Dilution Potential
4. Review Competitive Landscape

Key Dates

• 2025-12-29: S-1/A Filing — Registers the resale of up to 3,871,964 shares of common stock by selling stockholders, providing liquidity for certain investors.
• 2025-09-01: Securities Purchase Agreement — Resulted in the issuance of 1,098,902 unregistered shares and warrants for Series A and Series B shares, impacting potential future dilution.
• 2025-08-01: Securities Purchase Agreement with Hudson Global Ventures, LLC — Led to the issuance of 418,000 shares and a warrant, adding to the potential share count.
• 2024-12-31: Period End for Revenue Reporting — Company reported net revenues of $3.4 million, providing a snapshot of recent financial performance.

Glossary

S-1/A

An amendment to a registration statement filed with the U.S. Securities and Exchange Commission (SEC) for the purpose of registering securities for resale. (This filing indicates that existing shareholders are looking to sell their shares, potentially increasing the supply of stock in the market.)

Securities Purchase Agreement (SPA)

A contract between a buyer and a seller for the purchase and sale of securities. (These agreements are the source of many of the shares being registered for resale and the warrants being exercised.)

Warrants

A type of security that gives the holder the right, but not the obligation, to purchase a company's stock at a predetermined price (exercise price) within a specified timeframe. (The exercise of these warrants will result in the issuance of new shares, potentially diluting existing shareholders.)

Placement Agent Warrants

Warrants issued to the agents who helped facilitate a securities offering, typically as part of their compensation. (These represent additional shares that can be issued, contributing to potential dilution.)

Affiliate

A company or individual that is controlled by, or under common control with, another entity. (Many of the company's transactions and product developments involve affiliates, highlighting potential related-party risks.)

Restricted Shares

Shares of stock that have limitations on their sale or transfer, often issued as compensation or in private placements. (These shares are part of the compensation for licensing agreements and are subject to specific holding periods or conditions.)

Year-Over-Year Comparison

The provided context does not include information from a previous filing, making a direct comparison of key metrics impossible. However, the S-1/A filing indicates a significant number of shares (3,871,964) being registered for resale, suggesting a potential increase in market liquidity for existing shareholders. The company has also reported $3.4 million in net revenues as of December 31, 2024, and is pursuing strategic diversification, which may represent new growth avenues compared to prior periods.

Key Financial Figures

• $0.001 — res”), of common stock, par value $0.001 per share (“Common Stock”),
• $455,000 — te financing in the principal amount of $455,000 and (f) shares issuable under a warrant
• $4.34 — f Common Stock at a conversion price of $4.34 per share subject to customary adjustme
• $3.40 — d hereby will have an exercise price of $3.40 per share and will be exercisable upon
• $2.57 — ted sales price of our common stock was $2.57 per share. We are an “emerging
• $3.4 million — cember 31, 2024, we had net revenues of $3.4 million. We are strategically positioned to dri
• $350,000 — return for our paying a license fee of $350,000 in cash and a one-time grant of 1,000,0
• $14,818.06 — ber 31, 2025, at a base monthly rent of $14,818.06 (“Suite 125”). In light of
• $14,912.14 b — eed to pay a monthly termination fee of $14,912.14 base rent plus operating expenses for fiv
• $80,000 — or five months, saving us approximately $80,000 in lease payments for 2025. 4 On Ju
• $2,100,000 — a term loan in the principal amount of $2,100,000 with total interest of $924,000 (the &l
• $924,000 — nt of $2,100,000 with total interest of $924,000 (the “Loan”) to be repaid t
• $94,500 — ekly principal and interest payments of $94,500 commencing July 16, 2025, and ending Fe
• $100,000 — ruary 18, 2026, subject to payment of a $100,000 administrative agent fee paid to Agile

Filing Documents

• forms-1a.htm (S-1/A) — 332KB
• ex5-1.htm (EX-5.1) — 13KB
• ex23-1.htm (EX-23.1) — 5KB
• ex23-2.htm (EX-23.2) — 4KB
• ex23-1_001.jpg (GRAPHIC) — 13KB
• ex23-1_002.jpg (GRAPHIC) — 8KB
• ex23-2_001.jpg (GRAPHIC) — 11KB
• 0001493152-25-029277.txt ( ) — 400KB

Use of Proceeds

Use of Proceeds 9 Dividend Policy 9 Selling Stockholders 9 Description of The Securities That the Selling Stockholders Are Offering 12 Plan of Distribution 15 Legal Matters 16 Experts 17 Where You Can Find Additional Information 17 Incorporation of Certain Documents by Reference 17 i ABOUT THIS PROSPECTUS This prospectus describes the general manner in which the Selling Stockholders may offer from time to time up to 3,871,964 Shares (i) issued directly to the Selling Stockholders pursuant to the Securities Purchase Agreement or (ii) issuable upon the exercise of the Common Warrants issued pursuant to the Securities Purchase Agreement. You should rely only on the information contained in this prospectus and the related exhibits, any prospectus supplement or amendment thereto and the documents incorporated by reference, or to which we have referred you, before making your investment decision. Neither we nor the Selling Stockholders have authorized anyone to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus, any prospectus supplement or amendments thereto do not constitute an offer to sell, or a solicitation of an offer to purchase, the Shares offered by this prospectus, any prospectus supplement or amendments thereto in any jurisdiction to or from any person to whom or from whom it is unlawful to make such offer or solicitation of an offer in such jurisdiction. You should not assume that the information contained in this prospectus, any prospectus supplement or amendments thereto, as well as information we have previously filed with the U.S. Securities and Exchange Commission, or the SEC, is accurate as of any date other than the date on the front cover of the applicable document. If necessary, the specific manner in which the Shares may be offered and sold will be described in a supplement to this prospectus, which supplement may also a

View Full Filing

View this S-1/A filing on SEC EDGAR